RT @ericdeinmd: L05 #ACR22 High-dose Denosumab in Erosive Hand OA 48Wk, Double-blind PBO Phase 2 100 patients GUSS chang
Tweet Content
L05 #ACR22 High-dose Denosumab in Erosive Hand OA
48Wk, Double-blind PBO Phase 2 100 patients
GUSS change higher in DEN v PBO at w24, incr at w48
New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001)
Open label extension w improvement to baseline
@RheumNow https://t.co/X6MF9q2bKj
Show on Archive Page
On
Display in Search Results
On
PDQ
Off